Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aptose Biosciences, Inc. - Common Shares
(TSX:
APS
)
2.230
+0.010 (+0.45%)
Streaming Delayed Price
Updated: 2:41 PM EDT, Mar 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aptose Biosciences, Inc. - Common Shares
< Previous
1
2
3
4
Next >
Aptose Reports Results for the Third Quarter 2023
November 09, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
November 02, 2023
Data from the Ongoing APTIVATE International Phase 1/2 Study in Relapsed/Refractory AML Patients
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib
October 30, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023
October 26, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
October 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International Conference
October 16, 2023
Company to Hold Clinical Update Webcast; Details Forthcoming
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Present at the Cantor Global Healthcare Conference
September 18, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Closing of $3 Million Investment by Hanmi Pharmaceutical
September 06, 2023
— TUS/VEN doublet continues safe and effective in AML patients who failed prior venetoclax —
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
August 24, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Second Quarter 2023
August 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023
July 27, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance
June 26, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Presents Highlights from Clinical Update
June 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences Provides Update on Reverse Stock Split
June 05, 2023
Common Shares to begin trading on adjusted basis June 6
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Hold Interim Clinical Update Webcast on Saturday, June 10, 2023
May 31, 2023
EHA Abstract on Tuspetinib and Venetoclax Recently Published
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Enters into $25 Million Committed Equity Facility
May 25, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
May 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the First Quarter 2023
May 08, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
May 04, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
April 24, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
April 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
March 28, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Fourth Quarter and Full Year 2022
March 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
March 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
March 09, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
March 02, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
January 30, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
December 28, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences Establishes New At-The-Market Facility
December 12, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
December 11, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
